7-Ethyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)guanine manufacturers
|
| | 7-Ethyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)guanine Basic information |
| Product Name: | 7-Ethyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)guanine | | Synonyms: | 7-Ethyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)guanine;7-Ethyl-7,8-dihydro-8-oxo-9-(b-D-xylofuranosyl)guanine;7-Ethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine;2-amino-9-((2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7-ethyl-7,9-dihydro-3H-purine-6,8-dione | | CAS: | 2389988-43-4 | | MF: | C12H17N5O6 | | MW: | 327.3 | | EINECS: | | | Product Categories: | | | Mol File: | 2389988-43-4.mol |  |
| | 7-Ethyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)guanine Chemical Properties |
| Boiling point | 584.2±60.0 °C(Predicted) | | density | 2.04±0.1 g/cm3(Predicted) | | pka | 13.39±0.70(Predicted) |
| | 7-Ethyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)guanine Usage And Synthesis |
| Uses | 7-Ethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 7-Ethyl-7,8-dihydro-8-oxo-9-(beta-D-xylofuranosyl)guanine Preparation Products And Raw materials |
|